![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, April 23, 2018 5:38:02 PM
Japs are eager, same for some EU!
"Stay tuned",...LOL. Significant as we approach next approval as things will happen fast,especailly at this PPS,... so "more than daily DD" if you prefer! LMAO!
GL!
Recent AZN News
- IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial • Business Wire • 06/25/2024 11:00:00 AM
- IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer • Business Wire • 06/17/2024 11:00:00 AM
- CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial • Business Wire • 06/16/2024 11:00:00 AM
- FARXIGA approved in the US for the treatment of pediatric type-2 diabetes • Business Wire • 06/12/2024 09:35:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/12/2024 02:14:48 PM
- TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer • Business Wire • 06/10/2024 11:00:00 AM
- I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer • PR Newswire (US) • 06/06/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 08:23:12 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 06/04/2024 02:02:42 PM
- Economic Worries May Lead To Weakness On Wall Street • IH Market News • 06/04/2024 01:10:54 PM
- AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024 • PR Newswire (US) • 06/04/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 02:29:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 02:23:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 10:35:43 AM
- TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial • Business Wire • 06/02/2024 06:32:00 PM
- IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo • Business Wire • 06/02/2024 12:05:00 PM
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy • Business Wire • 06/02/2024 12:00:00 PM
- Cellectis Reports Financial Results for First Quarter 2024 • GlobeNewswire Inc. • 05/28/2024 08:30:00 PM
- ダトポタマブ デルクステカン、 進行性非扁平上皮非小細胞肺癌患者に対する第III相TROPION-Lung01試験において、 化学療法と比較して臨床的に有意な全生存期間の改善を示す • Business Wire • 05/28/2024 01:06:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 10:15:06 AM
- Datopotamab-Deruxtecan zeigt in Phase-III-Studie TROPION-Lung01 klinisch signifikante Verbesserung des Gesamtüberlebens im Vergleich zur Chemotherapie bei Patienten mit fortgeschrittenem nicht squamösem, nicht kleinzelligem Lungenkrebs • Business Wire • 05/27/2024 08:55:00 PM
- Le datopotamab deruxtecan a montré une survie globale cliniquement significative par rapport à la chimiothérapie chez des patients atteints d'un cancer avancé du poumon non à petites cellules et non squameux • Business Wire • 05/27/2024 05:14:00 PM
- Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial • Business Wire • 05/27/2024 11:00:00 AM
- AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) • Business Wire • 05/23/2024 05:52:00 PM
- AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) • Business Wire • 05/23/2024 11:00:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM